10QSB/A 1 trimedyne_10qa1-123101.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM 10-QSB/A QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTER ENDED COMMISSION FILE NUMBER DECEMBER 31, 2001 0-10581 ----------------- ------- TRIMEDYNE, INC. (Exact name of Registrant as specified in its charter) Nevada 36-3094439 (State or other jurisdiction (IRS Employer Identification Number) of incorporation or organization) 15091 Bake Parkway, Irvine, CA 92618 (Address of principal executive offices) (Zip Code) (949/559-5300) (Registrant's telephone number, including area code) Not Applicable (Former name, former address and former fiscal year, if changed since last report). Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), (2) has been subject to such filing requirements for the past 90 days. YES [X] NO [_] Indicate the number of shares outstanding of each of the issuer's class of common stock, as of the last practicable date. Class Outstanding at February 5, 2002 ---------------------------- ------------------------------------ Common Stock, $.01 par value 13,489,760 shares The Cash Flow Statement ha been amended to correct an error. TRIMEDYNE, INC. CONSOLIDATED STATEMENTS OF CASH FLOW (UNAUDITED)
Three Months Ended December 31, 2000 2001 ------------ ------------ (as restated) Cash flows from operating activities: Net Loss $(2,508,000) $ (113,000) Adjustment to reconcile net loss to net cash provided by (used in) operating activities: Depreciation and amortization 46,000 55,000 Impairment of inventory 219,000 -- Fair value of make-up shares 660,000 -- Gain on sale of fixed assets -- (17,000) Changes in operating assets and liabilities, net of acquisitions: (Increase) decrease in trade accounts receivable (485,000) 26,000 Decrease in inventories 104,000 205,000 (Increase) decrease in other current assets (94,000) 62,000 Increase (decrease) in accounts payable 387,000 (24,000) Increase (decrease) in accrued expense 29,000 (64,000) Decrease in other current liabilities -- (10,000) ------------ ------------ Net cash provided by (used in) operating activities (1,642,000) 120,000 Cash flows from investing activities: Capital expenditures (22,000) -- Sale of fixed assets -- 47,000 Sale of marketable securities 2,041,000 -- Acquisition of MST, net of cash received (1,000) -- ------------ ------------ Net cash provided by investing activities 2,018,000 47,000 Cash flows from financing activities: Payments on long-term obligations (7,000) (23,000) Loan from officer -- 63,000 ------------ ------------ Net cash provided by (used in) financing activities (7,000) 40,000 ------------ ------------ Net increase in cash and cash equivalents 369,000 207,000 Cash and cash equivalents at beginning of period 466,000 84,000 ------------ ------------ Cash and cash equivalents at end of period $ 835,000 $ 291,000 ============ ============ Non-cash investing and financing activities: Common stock issued for acquisition of MST $ 775,000 $ -- ============ ============
See accompanying notes to consolidated financial statements 5 SIGNATURE PAGE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. TRIMEDYNE, INC. Date: February 19, 2002 /s/ Marvin P. Loeb --------------------------- ------------------------------------ Marvin P. Loeb President and Chief Executive Officer Date: February 19, 2002 /s/ Jeffrey S. Rudner ---------------------------- -------------------------------------- Jeffrey S. Rudner Controller